News & Events

Government invests €40 million in 11 disruptive technologies projects across health and wellbeing, advanced robotics and machine learning

Disruptive Technologies Innovation Fund a major driver of Impact 2030 research and innovation strategy

The Tánaiste and Minister for Enterprise, Trade and Employment, Leo Varadkar TD, the Minister for Further and Higher Education, Research, Innovation and Science, Simon Harris TD and the Minister of State for Trade Promotion, Digital and Company Regulation, Dara Calleary TD today announced that 11 innovative projects have been approved funding of up to €40 million in the first tranche of awards under the fourth round of the Disruptive Technologies Innovation Fund.

Announcing the successful projects today the Tánaiste said:

“Today I have approved funding under the Disruptive Technologies Innovation Fund (DTIF) for another 11 ground-breaking projects that embody innovation and technological change.

“Now more than ever we should look to the future and embrace innovation as a means of building our capacity to conquer the challenges we face.

“Throughout the pandemic, the research community showed a commendable ability to adapt and rise to previously unthinkable challenges. We want to encourage and support that ingenuity and inventiveness through this fund, helping to deal with the adverse effects of COVID-19, Brexit, the war in Ukraine, and rising inflation.

“Projects announced today will benefit patients with heart failure, make online space safer for children and reduce greenhouse gases, paving the way for Ireland’s journey to a carbon neutral society, to name a few. These and other successful projects have identified emerging areas of opportunity in future markets to help solve societal challenges by building on our regional economic and research strengths.

“DTIF project partners continue to develop cutting-edge technologies and we will continue to invest in those enterprises and experts in the research community who apply innovative thinking to push boundaries and drive change.”

DTIF places a large emphasis on SME participation, to utilise their potential as drivers of disruptive innovation. The 11 successful consortia in this call have 40 partners, of which 58% (23) are SMEs and 10 of which are leading their projects. To date, 153 SMEs have been awarded funding in the four calls to date.

This brings the total allocation of DTIF funding to €275 million. Over €157 million (57%) of that funding has been awarded to project partners outside of Dublin. This will contribute to further economic growth in all regions and create high-quality jobs for talented people who live and work in rural Ireland.

Simon Harris, Minister for Further and Higher Education, Research, Innovation and Science said:

“This fund reinforces the significant impact research and innovation has on our industrial development and economic prosperity.

“Ireland continues to lead the world in research excellence, consolidated by our sustained commitment to research, development and innovation.

“This call includes many of Ireland’s talented and motivated research community which covers a wide range of disciplines. The diversity of these disciplines makes Ireland an attractive place for graduates to find sustainable long-term employment and gives enterprises, particularly SMEs, access to highly skilled talent.

“Of the 40 partners involved in this call, I am delighted to see that 15 research performing organisations have been awarded €15 million. This level of funding reaffirms our Government’s commitment to supporting Irish ingenuity and the development of cutting-edge technologies in our higher education institutions and universities.”

Dara Calleary TD, Minister of State for Trade Promotion, Digital and Company Regulation congratulating the successful projects said:

“Innovation through collaboration is a key part of Ireland’s success now and into the future. The DTIF calls are terrific opportunities for companies and research institutions to harness the potential of disruptive technologies, such as AI, and apply this to real-world problems.

“The 11 projects announced today demonstrate that such innovation is alive and well within the Irish ecosystem and that collaboration can lead to significant benefits to society as well identifying further opportunities for further growth. This ultimately is good for business and good for the economy and gives Irish enterprise the competitive edge when trading into new markets and an increasingly competitive global environment.”

Over the four calls announced to date, 123 research institutions are participating in 83 projects. Research institutions are involved in all bar two and are the lead partner in 18 projects.

Leo Clancy, CEO, Enterprise Ireland, who administer the Disruptive Technologies Innovation Fund, said:

“The investment offered through DTIF encourages Irish companies of all sizes, multinational companies and academic institutions to explore new opportunities by encouraging them to be more ambitious and pursue strategic research opportunities. It helps clients target investment in innovations in areas of major importance, such as future medical technologies and digitalisation.”


The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under the National Development Plan (NDP) in 2018. The Department of Enterprise, Trade and Employment manages the DTIF with administrative support from Enterprise Ireland. The purpose of the Fund is to drive collaboration between Ireland’s world-class research base and industry as well as facilitating enterprises to compete directly for funding in support of the development and adoption of these technologies. The aim is to support investment in the development and deployment of disruptive technologies and applications on a commercial basis.

Call 4 applications to DTIF were assessed by panels of international experts against four criteria – quality of the disruptive technology, excellence of overall approach, economic impact and sustainability, and strength of the collaboration.

Disruptive Technologies Innovation Fund (DTIF) – Awards under Call 4 (2021 – 2022)

DTIF Projects awarded are between €1.5 and €7 million in DTIF funding 

Project Description

Consortium Members

Research Priority Area

Regional Location

Total DTIF Award (in principle*)

VascuSense is a non-invasive device that will treat patients with chronic total occlusion, or complete blockages of coronary arteries that lead to critical limb ischemia.


1)    Versono Medical Ltd (LEAD)

2)    Integer Ireland Medical Ltd

3)    National University of Ireland, Galway (NUIG)

4)    Technology University Dublin (TUD)

Health & Wellbeing



Heallntel will capture multifaceted data to enable data-driven improvements to products and protocols associated with measuring and monitoring compression therapy and wound care.


1)    FeelTect Ltd (LEAD)

2)    Armour Interactive Ltd

3)    Odyssey Validation Consultants Ltd

4)    National University of Ireland, Galway (NUIG)

Health & Wellbeing



LILAC-IntelliSense is a software system that models a prognosis for Chemotherapy Induced Peripheral Neuropathy (CIPN) based on clinically obtained observations and smart bioinformatics algorithms, improving treatment outcomes while reducing long-term side effects.


1)    Luminate Medical Ltd (LEAD)

2)    Gentian Consultancy Services Ltd

3)    National University of Ireland Galway (NUIG)

4)    Trinity College Dublin (TCD)

Health & Wellbeing



Xbat+ will disrupt the global recycling market by identifying the potential hazards and risks associated with the Waste Electrical and Electronic Equipment (WEEE) recycling sector.

1)    University of Limerick (LEAD)

2)    Peregrine Technologies (Holdings) Ltd

3)    Somex Automation Teoranta

4)    Helgen Technologies Ltd

Energy, Climate Action and Sustainability



Ceroflo, Advant Medical and Galway-Mayo Institute of Technology (GMIT) will develop a DB stent that is more effective and efficient but will also eliminate pre-stent procedures and mitigate risks associated with conventional stent procedures

1)    Ceroflo Ltd (LEAD)

2)    Advant Medical Ltd

3)    Galway Mayo Institute of Technology (GMIT)

Health & Wellbeing



BioBlate will disrupt the current treatment of Diabetic Foot Ulcers and other mixed tissue infections by developing a non-invasive surgical device that delivers a high amplitude of electrical pulses to remove infected muscle and bone tissues, preserving the integrity of the wound bed to promote healing.

1)    Xtremedy Medical Ltd (LEAD)

2)    Design Partners Ltd

3)    National University of Ireland, Galway (NUIG)

Health & Wellbeing



This consortium seeks to develop Thorax: an AI-driven patient monitoring platform, combined with a diagnostic test capable of identifying patients at high risk of progression of acute diseases (sepsis/pneumonia).

1)    Novus Diagnostics Ltd (LEAD)

2)    Dolmen Design and Innovation Ltd

3)    National University of Ireland, Dublin (UCD)

4)    Royal College of Surgeons in Ireland (RCSI)

Health & Wellbeing



This project will develop a miniature implantable smart pump for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF) which limits the need for open-heart surgery.

1)    Pumpinheart Ltd (LEAD)

2)    Gentian Consultancy Services Ltd

3)    Boston Scientific Ltd

4)    Royal College of Surgeons in Ireland, RCSI

Health & Wellbeing



Cilter is an AI-driven parental control concept that will modify a phone at the kernel level to access all incoming and outgoing data and encrypt messaging apps.

1)    Cilter Technologies Ltd (LEAD)

2)    O'Neill Amarach Consultants Ltd

3)    Dublin City University




EncOVac will develop an orally self-administered vaccine technology delivered to intestinal mucosa to better protect against pathogens.

1)    Poolbeg Pharma (Ireland) Ltd (LEAD)                              

2)    Anabio Technologies UnLtd Company                                

3)    Trinity College Dublin (TCD)                                      

4)    National University of Ireland, Dublin (UCD)

Health & Wellbeing



RISOLVE proposes the developmentof a safe and effective personalised therapy that will disrupt the Overactive Bladder Treatment market using an innovative artificial intelligence-based digital platform.

1)    Amara Therapeutics Ltd (LEAD)

2)    TEKenable Ltd

3)    National University of Ireland Galway (NUIG)